Covagen Inks $146M Fynomer Discovery Pact with Mitsubishi
By Cormac Sheridan
Thursday, October 18, 2012
Covagen AG signed its first drug discovery deal, a pact worth potentially up to €112.25 million (US$146 million) with Mitsubishi Tanabe Pharma Corp. that involves its Fynomer protein scaffold technology.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.